KARA BOUTWELL: Open Payments
NPI 1275941601 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,526 in 124 payments from 41 companies in 2025. Trend: 2023 $2,496 · 2024 $2,529 · 2025 $2,526
Food & beverage: $2,526
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $292 |
| Daiichi Sankyo Inc. | 8 | $195 |
| Celgene Corporation | 6 | $173 |
| Janssen Biotech, Inc. | 10 | $162 |
| AstraZeneca Pharmaceuticals LP | 8 | $155 |
| Genentech USA, Inc. | 8 | $137 |
| Merck Sharp & Dohme LLC | 5 | $121 |
| E.R. Squibb & Sons, L.L.C. | 5 | $96 |
| Incyte Corporation | 4 | $85 |
| PFIZER INC. | 5 | $85 |
Products named: ENHERTU, REBLOZYL, OPDIVO, SCEMBLIX, KISQALI, IMFINZI, KEYTRUDA, ERLEADA.
Industry payments across AL — which companies pay providers there.
